Structural relationships between colonic mucin species were assessed using a library of monoclonal antibodies (MAbs) directed against purified human colonic mucin (HCM). After immunization of mice with purified mucin from normal human colonic mucosa, 14% of 1,920 fusion products screened were positive for anti-HCM activity in a solid-phase assay. Patterns of selective binding by hybridomas to six discrete HCM species (I-VI) separated by DEAE-cellulose chromatography suggested the presence of both shared and species-specific antigenic determinants among HCM species I-VI. 23 anti-HCMs MAbs (7 IgM, 7 IgGj, and 9 IgG2), demonstrating a range of anti-HCM species specificities, were produced and used to study structural relationships between mucin species. Binding of various mucin species by individual anti-HCM MAbs was shown by competitive solid-phase radioimmunoassay to reflect the presence of identical epitopes on the different species. Adsorption of HCM species on a variety of affinity resins prepared with anti-HCM MAbs demonstrated that binding to multiple mucin species by a single MAb was related to intrinsic structural determinants. Four anti-HCM MAbs recognized protease-sensitive antigenic structures, which suggests that they may be directed to core HCM proteins. 12 of the anti-HCM MAbs were shown by solid-phase assay to recognize either complete (n = 5) or partial (n = 7) isolated colonic mucin oligosaccharide side chains of defined structure. Collectively, these data show the presence of both shared and unique antigenic structural determinants among colonic mucin species. Chromatographic heterogeneity of mucin glycoproteins seems to be related to the existence of biologically significant subclasses in the normal human colon.
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Introduction
The abundant representation of mucin glycoproteins throughout the human colon suggests that they play an important role in colonic function (1) (2) (3) (4) . The importance of mucin in normal colonic function is underscored by the apparent association of alterations in mucin content with a variety of disease processes (5-1 1). However, insights into the functional properties of colonic mucin glycoprotein and the role of alterations in the pathophysiology of disease states have been limited by incom-plete knowledge of the composition and structure of normal mucin. Early studies in a variety ofanimals suggested that colonic mucin was composed of a single, polydisperse, high molecular weight glycoprotein (12) (13) (14) . More recently a number of workers have suggested that there may be subpopulations within purified colonic mucin from both experimental animals and humans (7, (15) (16) (17) (18) . Despite the increasing appreciation ofthe extensive heterogeneity of colonic mucin, the structural basis of this heterogeneity and its biological importance remain uncertain. Many studies have used incompletely characterized preparations or indirect structural methods, and demonstration of related functional consequences has been lacking (9, 13, (19) (20) (21) (22) .
Through our studies, we have attempted to expand our knowledge of the structure and function of normal human colonic mucin (HCM).' Purified normal HCM isolated from mucosa of fresh surgical specimens was found to contain at least five distinct mucin species as well as a sixth heterogeneous component recovered in a high salt wash after DEAE-cellulose chromatography (5) . Each HCM species (I-VI) appeared to have a distinctive hexose, hexosamine, and amino acid composition, which suggests that the chromatographically defined entities might differ in their fundamental structures. Similar analysis of colonic mucin from patients with ulcerative colitis demonstrated a selective decrease in one HCM species (IV). Although the basis for this deficit remains uncertain, subsequent studies have confirmed a selective reduction of species IV in specific association with this disease process (7) . Beyond its possible significance in the pathogenesis of ulcerative colitis, the apparent alteration in one HCM species independent of other components of HCM supports the concept that HCM subclasses may represent functionally distinct substances.
The structural relationship between HCM species remains unclear. Preliminary studies in this laboratory have focused on oligosaccharide side chain analysis of the most abundant HCM species (III, IV, and V). These studies have shown the presence of a complex array of at least 21 neutral and acidic oligosaccharide side chains which range in size from two to 12 sugar residues (23). Three different HCM species (III, IV, and V) were found to contain many common oligosaccharides. However, some oligosaccharides were identified only in individual components. Despite determination of the structures of some of the components of the complex mixture of oligosaccharide side chains attached to the HCM species, the fundamental structural relationships between HCM species require further evaluation.
In this report, we describe the production and characterization of a library of monoclonal antibodies (MAbs) directed against HCM and their use in the study of the structural relationships between HCM species. In an accompanying paper, we describe related studies using MAbs with defined anti-HCM specificity to examine colonic goblet cell function and the cellular basis of HCM heterogeneity.
Methods
Isolation, purification, andfractionation ofhuman colonic mucin, mucin species, and oligosaccharides Human colonic mucin was prepared from mucosal scrapings of fresh surgical specimens of normal human sigmoid colon from patients undergoing resection for diverticulosis. Pure mucin was isolated from materials solubilized by sonication using sequential Sepharose 4B column chromatography and CsCl density centrifugation as previously described (5) . Individual mucin species I-VI were separated on DEAE-cellulose column chromatography. Neutral and acidic oligosaccharides were isolated from HCM species III, IV, and V by sequential chromatography after alkaline degradation (23). Oligosaccharide structures were determined by combination of permethylation analysis and sequential glycosidase digestion (23).
Preparation ofanti-human colonic mucin monoclonal antibodies (anti-HCM MAbs)
Immunization. Primary immunization of Balb/c mice (Charles River Breeding Laboratories, Wilmington, MA) was carried out with unfractionated pure human colonic mucin (100 ug) by intravenous injection. Secondary and tertiary immunizations identical in route and amount were accomplished at subsequent 3-5-wk intervals. All animals received further doses of antigen on days 4 and 3 before fusion.
Fusion technique and production of monoclonal antibodies. Splenocytes from immunized animals were prepared and fused with P2-NSl/l-Ag 4-1 (NSl) myeloma cells essentially as described (24) (25) (26) . Hybrids were selected by use of medium containing hypoxanthine/aminopterin/thymidine (HAT) on days 3, 4, and 5 after fusion. Medium from surviving hybrids was assessed for anti-HCM activity after transferring to 24-well culture plates (Costar, Cambridge, MA). Positive primary hybridomas were grown to confluence in Dulbecco's modified Eagle's medium supplemented with 20% fetal calf serum in 60-mm dishes and assessed for activity against individual HCM species I-VI. Hybrids with a range of anti-HCM species specificities were double-cloned at limiting dilution in complete medium on 3T3 monolayers previously treated with mitomycin C (1 Mg/ml). After Competitive RIAs were performed by two-stage solid-phase assay. Supernatant recovered after initial incubation of beads coated (as described above) with an antigen being assessed for its cross-reactivity (unfractionated mucin, individual mucin species, or isolated mucin species oligosaccharides) was transferred and incubated under comparable conditions with a second bead coated with the reference HCM species antigen. Controls included samples incubated with beads coated with either bovine serum albumin (negative control) or the reference HCM species or unfractionated HCM (positive controls) during the first phase incubation.
Structural determinants specified by MAbs were assessed in solidphase sandwich assays using a panel of beads coated with individual isolated mucin species (III, IV, and V) oligosaccharides in assays similar to those described above. Isolated oligosaccharides (10-100 sAg/ml) were incubated with polystyrene beads (2 beads/ml) in 0.1 M bicarbonate buffer, pH 9.2 (acidic oligosaccharides), or 0.1 M Nacacodylate, pH 6.5 (neutral oligosaccharides) in the presence of0.1% Na azide (wt/vol) overnight at room temperature with gentle shaking. Binding of individual oligosaccharides was quantitated by addition of oligosaccharide radiolabeled at the reducing terminus during initial alkaline cleavage (23) (specific activity, 1.4-2.7 X 106 cpm/,m N-acetylgalactosaminitol). Final concentrations were adjusted to achieve a specific activity of 1.0 X 106 cpm/Mm oligosaccharide. Maximum binding of oligosaccharides ranged from 0.1 to 1.4 X lO-' M/bead. To standardize oligosaccharide binding studies to permit assessment of relative binding, we adjusted amounts of oligosaccharides used during the coating process to achieve final concentration of 1.0±0.1 X 10`0 M oligosaccharide/bead. Before use, sites of nonspecific binding were blocked as above. Beads were stored up to 1 wk at 0-4°C. After incubation of the individual MAb with oligosaccharide-coated beads, bound radiolabel after incubation with the Fab probe was assessed as before. Supernatants from initial incubations were added to beads coated with intact mucin species to determine the effect of this prior adsorption on binding to the intact mucin glycoprotein.
Effect ofprotease treatment ofHCM
Purified HCM was suspended (1 mg/ml) in 0.01 M Tris-HCl, pH 7.5 with 0.01 mg CaCl2 and 0.01% Na azide (wt/vol) and digested with Pronase (1% wt/vol) (Sigma Chemical Co., St. Louis, MO) at 45°C overnight. Digestion was stopped by heat inactivation (80°C, 20 min) and beads were coated with the mixture as described above. Control assays included a HCM and Pronase mixture heat-inactivated at zero time. Pilot studies with intact HCM labeled at nonreducing termini as previously described (7) indicated equivalent binding to beads of radiolabel from the pronase digest and zero time control incubation. Treatment of 1.4 X 106 cpm 3H-labeled HCM followed by incubation with 50 beads suspended in 0.1 M Na bicarbonate buffer, pH 9.2, resulted in a specific activity of 4.8±0.5 X 102 cpm/bead for the zero time control and 4.1±0.4 X 102 cpm/bead after overnight digestion. Efficacy of pronase treatment was confirmed by chromatography on Sepharose 4B as previously described (7); >85% of radiolabeled HCM was found to migrate in the included volume after pronase digestion in contrast to <5% in the untreated material.
MAb affinity absorption ofHCM species
Purified anti-HCM MAbs (3.3 mg) were individually coupled to CNBractivated Sepharose 4B (1.0 g) using previously described methods (29). Coupling was '70% efficient as determined by retention of tracer 1211_ MAbs radiolabeled using the Bolton-Hunter reagent (30) . Affinity resin was packed in a Pasteur pipette and sample (200 Ml) of individual mucin species (0.1 mg/ml 0.1 M Tris-HCI pH 8.0) applied at room temperature. The column was clamped for 30 min and then washed with 15 ml of application buffer, collecting 1.0 ml fraction. Mucin species content of eluant was assessed by coating polystyrene beads as described above with individual fractions followed by addition of anti-HCM MAbs ascites (either the same MAb conjugated to the affinity resin or one with an appropriate mucin species specificity) using conditions described above. Control chromatography was performed using uncoupled Sepharose 4B or resin conjugated with a non-cross-reacting MAb directed against a serum galactosyltransferase (29).
Results
Monoclonal antibodies were produced from mice immunized with normal human colonic mucin and characterized for their mucin species specificities. Human colonic mucin was found to be highly antigenic. Anti-HCM titers were routinely found to be >1:104 after an initial boost following a primary immunization. After fusion of splenocytes from immunized mice with a nonproducing myeloma line, 14% of 1,920 products had measurable anti-HCM activity in a solid-phase sandwich assay (12-21% among seven separate fusions). Results of determination of anti-HCM activity by solid-phase RIA of positive hybridomas from a representative fusion are depicted in Fig. 1 Table  I , which summarizes the characteristics ofsome positive hybrids obtained from three fusions. These primary fusion products included a group of anti-HCM hybridomas that appeared to recognize individual species II, III, IV, V, and VI. No hybridomas reacted uniquely with mucin species I. In addition to hybridomas that appeared to recognize determinants on a single mucin species, other fusion products recognized determinants common to two or more species, including in some instances all six species. Certain combinations were repeatedly encountered including hybridomas recognizing species III, and IV, IV, and V, III and VI; IV and VI; III, IV, and V; IV, V, and VI; III, IV, V, and VI; I, II, III, IV, and V; and I-VI. Finally, a number of fusion products were obtained which did not appear to react with any of the separated species in solid-phase sandwich assay despite initial demonstration of positivity against pure unfractionated HCM. Confirmation that these latter hybridomas were directed against HCM determinants and not contaminants was obtained by indirect immunofluorescent studies (31) .
Efforts were directed at the production of MAbs exhibiting the range ofHCM species specificities observed in initial hybridomas and summarized in Table I . Stable MAb-producing cultures could not be established from all representative initial hybridomas cultures. However, it was possible to develop a library ofanti-HCM monoclonal antibodies, which included MAbs with many of the different mucin species recognition patterns found I, II, III, IV, V   II   IV, VI  III, IV, V  0  III, IV   II, IV  I, II, III, IV, V, VI   V   III, IV, V  IV, V, VI   I, II, III, IV, V   III  III, IV, V  II, IV I, II,-III, IV, V, VI * Supernatant from representative primary products of three separate fusions after achieving near confluent growth in 24-well plates. t Polystyrene beads were coated with either unfractionated pure HCM or separated mucin species I-VI prepared as previously described (5) Competitive solid-phase RIAs were performed to determine the similarity ofthe determinants present on the different mucin species recognized by those anti-HCM MAbs that reacted with multiple mucin species. These studies assessed the reduction of MAb binding to one HCM species after prior incubation with beads coated by a different HCM species also recognized by that MAb. The results ofa representative analysis ofone multi-species specific MAb are demonstrated in Fig. 2 . In this instance, prior incubation of MAb 4 (previously shown to bind isolated mucin species III, IV, and V; Table II) with mucin species III or IV effected a linear inhibition of binding to mucin V (Fig. 2 C) . Conversely, species V caused reciprocal inhibition of binding to species III (Fig. 2 A) and IV (Fig. 2 B) hibition of binding by appropriate HCM species in competitive RIAs.
Subsequently, adsorption chromatography was performed to determine whether apparently equivalent binding to determinants on different colonic mucin species by single anti-HCM MAbs reflected the presence of shared integral structural components or unappreciated cross-contamination of the mucin species preparations. Initial adsorption studies used resins conjugated with a MAb that bound multiple HCM species. As shown in Table III , Sepharose 4B conjugated with pure MAb 1 (recognizing HCM species IV and V by solid-phase RIA) adsorbed either mucin IV or mucin V. Adsorption of both mucin species IV and V by a single MAb was confirmed by the elimination of binding reactivity to the column eluant by monospecific MAbs directed against either mucin IV (MAb 14) or mucin V (MAb6).
In a reciprocal study, affinity resin was prepared using a monospecies-specific anti-HCM MAb. As shown in Table IV , application of mucin species IV to Sepharose 4B conjugated with MAb 14 (specific for species IV by solid-phase RIA), resulted in effective adsorption of this substance alone as indicated by the reduction in binding to the eluant by the multispecies-specific MAb 1, which was not observed when HCM species V was also applied to the column.
Next, a HCM species was conjugated to Sepharose 4B to determine if adsorption of a multispecies-specific MAb resulted in parallel loss of binding activity to all species recognized by that MAb. In representative experiments, MAb 1 was applied to HCM V-Sepharose 4B. As indicated in Table V Tables I and II. 14 (recognizing IV only) and MAb 6 (recognizing V only) were applied to this same matrix. Collectively, these data suggest that MAb 1 binds an intrinsic and identical determinant on both species IV and V, which differs from the determinant on species IV recognized by MAb 14. Conversely, MAb 14 must bind a determinant of species IV that is not present on species V.
The actual structural determinants recognized by anti-HCM MAbs were studied by solid-phase sandwich RIA using beads coated with oligosaccharides of defined structure isolated from HCM species III, IV, and V. Each MAb was assessed for binding activity using a panel of 37 oligosaccharides isolated from mucin species III, IV, and V encompassing 21 discreet defined structures (23). Results of binding determinants of individual MAbs to each of the 21 structures are detailed in 
GalNac-ol but not to the other 20 different oligosaccharide structures studied. Note that this oligosaccharide was isolated from mucin species IV and V, which corresponds to the binding specificity ofthis MAb (see Table II ). This anti-HCM MAb did not bind to closely related but smaller structures (e.g., Galf3 (14), GlcNacfl(1-3)GalNacol), indicating specificity for the intact structure.
Seven anti-HCM MAbs bound more than one oligosaccharide side chain. In each instance, when a single MAb recognized more than one oligosaccharide, these different side chains contained common structural components. The structural determinants specified by these seven anti-HCM MAbs could be deduced from comparative analysis of the structures of the oligosaccharides bound. In a representative series of assays, MAb 4 bound a number of diverse oligosaccharides structures (Table   VI) . However, all ofthe oligosaccharides recognized by this MAb contained one trisaccharide, Gal#B(1-4)GlcNacj3(1-3)Gal(l (1-x) , at or near the nonreducing terminus although this trisaccharide was not found as a discrete independent structure. Oligosaccharides lacking this trisaccharide were not recognized by MAb 4.
The structures of the apparent antigenic determinants of 12 anti-HCM MAbs derived from the data presented in Table VI  are summarized in Table VII and include oligosaccharides containing two to nine carbohydrate residues. Binding specificity of these 12 MAbs to species III, IV, and V correlated with the presence ofthese oligosaccharide structures in the mucin species; Table II . Solid-phase RIA or supernatant pre-or post-adsorption of anti-HCM MAbs with Sepharose 4B-HCM V resin using beads coated with either HCM species IV or V as described in Methods; cpm bound/bead after subtraction of blank control determined as described in legend to Table III. e.g., MAb 5 specifically bound to oligosaccharides containing the structure NeuAca(2-6)Galfl(l-4)GlcNac3(l-3)[NeuAca(2-6)]GalNac-ol, which was present in HCM species IV and V (but not III), mirroring the binding specificity of this MAb in initial solid-phase RIA. Not surprisingly, MAbs recognizing more limited structural determinants were among those exhibiting broader HCM species specificities in solid-phase RIA. This finding is illustrated by MAb 11, which appeared to recognize the limited
and was relatively nonspecific in its RIA-defined HCM species binding properties, recognizing species III, IV, and V (as well as VI). In a manner similar to MAb 4, the oligosaccharide GalNaca(I-3)[Fuca(1 -2)]Galf3( l-x) specified by MAb 11 was not isolated as a discreet structure in any of the mucin species III, IV, and V but reflects a component common to more extended oligosaccharides which are themselves distinct, i.e.,
Nac-ol in HCM species V. It appears that the demonstration of binding to multiple HCM species by individual MAbs does not necessarily indicate the presence of identity of intact structures but can be related to recognition of limited determinants. To provide insight into the nature of the structural determinants specified by 11 anti-HCM MAbs that did not bind the available isolated HCM oligosaccharides, the effect of nonspecific proteolytic digestion of HCM on subsequent binding was determined. Prolonged exposure of HCM to Pronase was found to effect a marked alteration in apparent size as judged by Sepharose 4B chromatography; >85% of material radiolabeled at nonreducing terminus appeared in the included volume following digestion. As noted in Table VIII , binding of four anti-HCM MAbs (2, 8, 10, 17) was significantly reduced after protease digestion of HCM, which suggests that these MAbs may be directed to components of the protein core. Note that protease digestion HCM appeared to bind to beads with an efficiency equivalent to the intact material, indicating that the impaired binding was not simply an effect of diminished adherence of the antigen to the bead. Furthermore, protease treatment had little effect on subsequent binding by those MAbs recognizing other antigenic structures (e.g., MAb 1; Table VIII ). Alternatively diminished binding by some MAbs after protease treatment ofthe antigen may reflect a requirement for extended conformational features rather than recognition of a protein determinant per se. Binding to HCM by the 12 MAbs previously found to recognize oligosaccharide side chain structures was less affected by the protease (e.g., MAb 1 included for comparison in Table VIII ). The nature of the structural determinants recognized by the remaining seven anti-HCM MAbs whose binding in solid-phase RIA was neither related to available oligosaccharides nor affected by protease treatment remains unknown.
Discussion
Previous work in this laboratory has suggested the presence of at least six structurally distinct species of mucin glycoprotein in the normal human colon (5, 7) . The observation of a specific and selective reduction of mucin species IV in association with ulcerative colitis, independent of changes in other mucin components, suggests that distinctions made on the basis of chromatographic and compositional properties reflect biologically meaningful heterogeneity (5, 7, 32) . However, these early studies were unable to assess the relatedness ofthe chromatographically defined mucin subclasses. Therefore, efforts reported here were undertaken to develop and characterize anti-HCM MAbs as probes for the further study of HCM structure and function. The results of the studies reported here have been augmented by conventional structural analysis of mucin oligosaccharides carried out in parallel (23).
HCM was found to be highly immunogenic in mice. Hybridomas showed a broad spectrum of relative selectivity for isolated HCM species, ranging from recognition of single HCM species to broad reactivity with all HCM species (Table I) . These findings with uncloned fusion products indicate that each HCM species possesses "private" structural determinants as well as "common" structural features, which are shared to varying extent among the different species. At the same time they suggest that each species is distinct and not (antigenically) a subpopulation of another. It is of interest that some anti-HCM hybridomas recognized combinations of species with markedly divergent chromatographic elution properties (e.g., HCM species II and V), supporting the notion that separation into HCM species did not reflect arbitrary partition of a polydisperse substance.
These conclusions are further substantiated by the results of studies carried out with MAbs. Characterization of these stable reagents confirmed the presence of both shared and unique antigenic determinants among the HCM species. Various HCM species competitively inhibited binding of other species to multispecies-specific MAbs, supporting the conclusion that the different species contained some equivalent antigenic structures (Fig. 2) . Although these findings could reflect the presence of cross-contamination between the mucin species recovered from ion exchange resin, this seems unlikely for several reasons. First, as noted above, some multispecies-specific MAbs were found to 
HCM subspecies determined by solid-phase RIA as described in text and Table II . * Oligosaccharide isolated from HCM species III, IV, V as described (23); specificity of MAbs determined as described in text and derived from data presented in Table VI (Table V) . Collectively, these studies indicate that the determinants recognized by the MAb are in each instance integral structures of the mucin species bound. As a corollary, these data support the concept that the determinants on a particular mucin species recognized by different MAbs are distinct but reside on the same molecule. A number of multispecies-specific MAbs were noted to recognize relatively circumscribed structural determinants ( Table   Table VIII These observations indicate that solid-phase binding studies using intact glycoproteins could lead to overestimation of the extent of biologically significant structural homology. These studies also indicate that reagents directed at smaller determinants may be insufficiently discriminating to distinguish biologically significant structural differences among glycoproteins. Indeed, several earlier studies have utilized probes directed to circumscribed nonreducing terminal structures to explore colonic mucin heterogeneity. These probes have included lectins that recognize terminal monosaccharides or disaccharides (18, 22, 33, 34) , histochemical stains that bind peripheral charged residues (1 1, 30, 35, 36) or conventional antisera directed at limited peripheral carbohydrate determinants (17, 37, 38) . The present results suggest that relatively nonspecific tools may both underestimate heterogeneity and overestimate structural homologies. These findings show the importance of defining the antigenic determinants recognized by MAbs before they can be meaningfully used to assess structural relationships.
The presence and nature of oligosaccharides common to different mucin species were shown by the identification of the antigenic determinants recognized by MAbs that bound multiple HCM species. Conversely, and perhaps more importantly, isolation of MAbs with defined antigenic determinants that recognized only a single HCM species confirms the structural relevance of the chromatographic distinctions made in separating these entities.
Note that several anti-HCM MAbs failed to bind separated HCM species despite recognition of unfractionated HCM. While it is possible that these MAbs are directed to contaminating nonmucin components, this seems unlikely in view of the avid staining of goblet cell mucin droplets found in related studies (31) . This apparent paradox may reflect limitations of the assay methodology used. Conformational presentation ofthe relevant structural determinant may be lacking on the solid phase used for sandwich RIA in these studies. Alternatively, the assay conditions used may not facilitate MAb binding because of the nature ofthe antigenic determinant or properties ofthe MAb itself.
However, failure to demonstrate solid-phase binding to the separated species for these technical reasons is difficult to reconcile with the ability to effect binding to the unfractionated preparations. Alternatively, these MAbs may be directed to components of HCM which are not recovered from the DEAE-cellulose column used to separate HCM species. As previously reported, recovery of HCM after ion exchange chromatography is <84% and it is possible that minor mucin constituents recognized by these MAbs are lost during these procedures.
In summary, development and characterization ofanti-HCM MAbs has confirmed the presence of structurally distinct subclasses of HCM that nonetheless share some common oligosaccharide side chains. While much further study will be necessary to define the structure of normal HCM species, these MAbs should prove particularly useful. Use of MAbs recognizing defined antigen determinants will permit assessment ofthe presence of these structures in uncharacterized mucin species from the colon as well as mucin from other sites. Further, the availability of MAbs that appear to recognize protein determinants should facilitate isolation and characterization ofHCM peptides. It will be especially important to learn whether HCM species possess distinctive protein cores reflecting different gene products. Efforts are under way to exploit anti-HCM MAbs for efficient purification and quantitation of total HCM and component species. Finally, the demonstration of the presence of multiple and distinct HCM species raises the question of the functional and cellular significance of this heterogeneity. A companion report contains initial attempts to address the latter issue using anti-HCM MAbs and indirect immunofluorescence techniques to localize HCM species in goblet cells in situ (31) .
